SCHEMBL785938

SCHEMBL785938

CC1(C)CC2(CCC1=O)OCCO2

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19965585 0.90 POLB (0.31) POLBMAPT
SCHEMBL14265654 0.78 MAPT (0.31) POLBMAPT
SCHEMBL22578076 0.77
SCHEMBL26983602 0.76 PTPN1 (0.31)
SCHEMBL9981990 0.76 METAP2 (0.30)
SCHEMBL25213730 0.75
SCHEMBL17621259 0.73 ALDH1A1 (0.30) KMT2A
SCHEMBL1057403 0.73 L3MBTL1 (0.32) POLB
SCHEMBL14498503 0.72 POLB (0.30) POLBMAPT
SCHEMBL46361 0.72 KMT2A (0.34) POLBMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615848-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF Ribometrix, Inc. (US) 2025-09-17 EP disclosed
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
WO-2024238406-A1 FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF FRONTIER MEDICINES CORPORATION (US) 2024-11-21 WO disclosed
US-20240246979-A1 cGAS INHIBITORS ELI LILLY AND COMPANY 2024-07-25 US disclosed
US-20240246918-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF RIBOMETRIX, INC. 2024-07-25 US disclosed
WO-2024137752-A1 AZEPINO[4,5-B]INDOLONE CGAS INHIBITORS ELI LILLY AND COMPANY (US) 2024-06-27 WO disclosed
WO-2024103069-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 WO disclosed
US-20240000119-A1 MEGASTIGMANE DERIVATIVE COMPOSITIONS AND METHODS FOR TASTE MODULATION INTERNATIONAL FLAVORS & FRAGRANCES INC. 2024-01-04 US disclosed
CN-110582485-B Pyrazole derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-13 CN disclosed
EP-4250958-A1 MEGASTIGMANE DERIVATIVE COMPOSITIONS AND METHODS FOR TASTE MODULATION International Flavors & Fragrances Inc. (US) 2023-10-04 EP disclosed
US-7235698-B2 Enantioselective, catalytic allylation of ketones and olefins CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-06-26 US disclosed
WO-2006102097-A2 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2006-09-28 WO disclosed
US-7067527-B2 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
EP-1259515-B1 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA PHARMACEUTICAL (JP) 2004-11-10 EP disclosed
US-20040054183-A1 Thienopyridine derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-18 US disclosed
US-6653476-B2 Antiinflammatory and antiarthritic agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-11-25 US disclosed
US-20030130517-A1 Thienopyridine derivatives , their production and use TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-10 US disclosed
EP-1259515-A2 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-11-27 EP disclosed
WO-2001064685-A2 THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-09-07 WO disclosed
US-5547960-A ACETYLCHOLINESTERASE INHIBITORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1996-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130517-A1 Thienopyridine derivatives , their production and use ALK, HRH2, TBXA2R POLB 2530/4885MAPT 3749/4885KMT2A 866/4885
US-20240246918-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF EIF4E, EIF4EBP1, EIF4A1 POLB 1373/4885MAPT 1449/4885KMT2A 2630/4885
US-20240246979-A1 cGAS INHIBITORS CGAS, STING1, IRF3 POLB 282/4885MAPT 1847/4885KMT2A 4033/4885
US-20040054183-A1 Thienopyridine derivatives, their production and use ALK, HRH2, TBXA2R POLB 2530/4885MAPT 3749/4885KMT2A 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.